Health Canada has approved Novartis Canada’s Fabhalta (iptacopan capsules) as the first oral monotherapy to treat adults with ...

Novartis Canada is pleased to announce that Health Canada has granted a Notice of Compliance for Fabhalta® (iptacopan ...

Travere’s stock price climbed by 14% following the announcement it will seek an FDA label expansion for Filspari.

The Swiss pharmaceutical company has set a high bar for any potential obesity-treatment acquisition as it scans the market ...

If there were an official hierarchy of qualities that dividend seekers should consider before investing in a stock, a company ...

Now turning to Fabhalta. As you're well ... And free cash flow grew 24% to $16.3 billion, a record high for Novartis. Now speaking of free cash flow, let's turn to the next slide.

Novartis Q4 earnings beat estimates with sales up 16%, driven by strong demand for Entresto, Kesimpta, and Cosentyx. CEO Narasimhan reportedly downplays Entresto's U.S. patent expiration ...

BASEL (dpa-AFX) - February is observed as American Heart Month, a period dedicated to raising awareness about heart health. The first American Heart Month was officially declared by President ...

An FDA panel is scheduled to review Novartis' (NVS) application seeking approval for the expanded use of its drug Fabhalta to treat adults with complement 3 glomerulopathy on February 24 ...